Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

被引：0
|
作者：
Chen, Emily L.
Hawkey, Nathan
Thomas, Beatrice C.
Ware, Kathryn E.
Runyambo, Daniella
Caligiuri, Maureen
Wilker, Erik
Soderblom, Erik J.
Moseley, M. Arthur, III
Guichard, Sylvie M.
Armstrong, Andrew J.
Somarelli, Jason A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P204
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader
    Luo, Jie
    Prolia, Abhijit
    Qiao, Yuanyuan
    Tian, Jean
    Mannan, Rahul
    Mahapatra, Somnath
    Chen, Zhixiang
    Seri, Rithvik
    Wang, Shaomeng
    Chinnaiyan, Arul
    CANCER RESEARCH, 2024, 84 (06)
  • [22] INHIBITION OF p300/CBP SUPPRESSES CASTRATION-RESISTANT PROSTATE CANCER
    Lasko, L. M.
    Jakob, C. G.
    Edalji, R. P.
    Qiu, W.
    Montgomery, D.
    Digiammarino, E. L.
    CANCER DISCOVERY, 2017, 7 (11) : 1215 - 1215
  • [23] Targeting epigenetic regulatory machinery to overcome cancer therapy resistance
    Guo, Lei
    Lee, Yi-Tsang
    Zhou, Yubin
    Huang, Yun
    SEMINARS IN CANCER BIOLOGY, 2022, 83 : 487 - 502
  • [24] The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors
    Wu, Xin
    Zhang, Xin
    Tang, Shaoshan
    Wang, Yao
    CELL BIOLOGY AND TOXICOLOGY, 2025, 41 (01)
  • [25] AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
    Sardar, Sumaira
    McNair, Christopher M.
    Ravindranath, Lakshmi
    Chand, Saswati N.
    Yuan, Wei
    Bogdan, Denisa
    Welti, Jon
    Sharp, Adam
    Ryan, Natalie K.
    Knudsen, Liam A.
    Schiewer, Matthew J.
    DeArment, Elise G.
    Janas, Thomas
    Su, Xiaofeng A.
    Butler, Lisa M.
    de Bono, Johann S.
    Frese, Kris
    Brooks, Nigel
    Pegg, Neil
    Knudsen, Karen E.
    Shafi, Ayesha A.
    ONCOGENE, 2024, 43 (43) : 3197 - 3213
  • [26] CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond
    Hu, Jiankang
    Xu, Yong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (07) : 5272 - 5274
  • [27] Roles of the acetyltransferases CBP/p300 in breast cancer
    Muhmud, Iqbal
    Tian, Guimei
    Liao, Daiqing
    CANCER RESEARCH, 2017, 77
  • [28] Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
    Santer, Frederic R.
    Hoeschele, Philipp P. S.
    Oh, Su Jung
    Erb, Holger H. H.
    Bouchal, Jan
    Cavarretta, Ilaria T.
    Parson, Walther
    Meyers, David J.
    Cole, Philip A.
    Culig, Zoran
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (09) : 1644 - 1655
  • [29] Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP
    Zucconi, Beth E.
    Makofske, Jessica L.
    Meyers, David J.
    Hwang, Yousang
    Wu, Mingxuan
    Kuroda, Mitzi I.
    Cole, Philip A.
    BIOCHEMISTRY, 2019, 58 (16) : 2133 - 2143
  • [30] Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer
    Choo, Nicholas
    Keerthikumar, Shivakumar
    Ramm, Susanne
    Ashikari, Daisaku
    Teng, Linda
    Niranjan, Birunthi
    Hedwards, Shelley
    Porter, Laura H.
    Goode, David L.
    Simpson, Kaylene J.
    Taylor, Renea A.
    Risbridger, Gail P.
    Lawrence, Mitchell G.
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 242 - 256
12345